{"id":1701,"date":"2022-11-21T13:43:25","date_gmt":"2022-11-21T12:43:25","guid":{"rendered":"https:\/\/avextra.com\/?page_id=1701"},"modified":"2026-03-06T11:50:53","modified_gmt":"2026-03-06T10:50:53","slug":"media","status":"publish","type":"page","link":"https:\/\/avextra.com\/en\/ueber-avextra\/media\/","title":{"rendered":"Media"},"content":{"rendered":"
Home<\/a><\/span><\/span>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

Press Releases<\/h1>\n\n\n\n

Please find the latest press releases from Avextra here.<\/p>\n<\/div>\n\n\n\n

\n
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div>
\"Gro\u00dfer<\/a><\/div>

Gro\u00dfer Schritt zu mehr Klarheit: Patientenversorgung sichern<\/a><\/h3>

Bensheim, 12. August 2026 \u2013 Was die neue Auslegung zur Cannabis-Vorrangregelung f\u00fcr \u00c4rzte und Apotheken bedeutet\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Mehr<\/a><\/div>

Beyond Oil: Avextra Launches Novel Cannabis Granulate \u2013 A new perspective in patient care<\/a><\/h3>

Bensheim, June 30, 2026 \u2013 Avextra is introducing a novel cannabis granulate based on a balanced THC\/CBD extract, designed for the preparation of capsule-based formulations\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Neues<\/a><\/div>

Neues Dronabinol-Konzentrat optimiert Rezepturherstellung in der Apotheke<\/a><\/h3>

Bensheim, 5. Mai 2026 \u2013 Avextra erweitert mit dem Dronabinol Konzentrat Avextra 31 mg\/ml sein Portfolio an cannabisbasierten Rezepturarzneimitteln…<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Novel<\/a><\/div>

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance<\/a><\/h3>

Bensheim, Germany, December 3rd 2025 \u2014 How can therapy with Cannabis-based medicines (CbM) be designed to be not only therapeutically proven, but also patient-friendly and safe\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines for Neurodegenerative Diseases<\/a><\/h3>

First patient enrolled in randomized, placebo-controlled study\n\nBensheim, 24. October 2025 \u2013 Neurodegenerative diseases represent one of the biggest challenges of our time. In Germany alone, there are currently...<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"First<\/a><\/div>

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial<\/a><\/h3>

Bensheim, Germany, August 11, 2025 \u2013\u00a0PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin…<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Avextra<\/a><\/div>

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients<\/a><\/h3>

Bensheim, Germany, 13th June 2025 \u2014 New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines\u2026<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div>
\"Veteran<\/a><\/div>

Veteran Banker Joins Avextra\u2019s Supervisory Board<\/a><\/h3>

Bensheim, Germany, April 3, 2025 \u2013 Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra\u2019s Supervisory Board,…<\/p>\n<\/div>

read more\n \n<\/svg>\n<\/a><\/div><\/div><\/div><\/div><\/div>